Routine board addition with no immediate financial catalyst. Monitor upcoming Phase 2b data readouts for MAR001 (severe hypertriglyceridemia) and MAR002 (acromegaly) as the primary value drivers.
Price Chart
Executive Summary
Lisata Therapeutics appointed Jeffrey Farrow to its Board of Directors, filling a newly created seat (expanding the board from seven to eight members) and joining the Audit Committee. Mr. Farrow is a veteran biopharma CFO with experience at Tarsus Pharmaceuticals, Global Blood Therapeutics, ZS Pharma, and Hyperion Therapeutics, all of which were acquired. This is a routine board appointment with no financial terms disclosed and no departure of existing officers.
Key Facts
- Board expanded from 7 to 8 members; Jeffrey Farrow appointed as Class III director effective October 13, 2026
- Farrow also appointed to the Audit Committee
- Farrow is CFO and Chief Strategy Officer of Tarsus Pharmaceuticals (Nasdaq: TARS) since April 2023
- Farrow previously served as CFO of Global Blood Therapeutics (acquired by Pfizer), ZS Pharma (acquired by AstraZeneca), and Hyperion Therapeutics (acquired by Horizon Therapeutics)
- No compensation or employment agreement terms disclosed in the filing
- No family relationships or transactions requiring disclosure under Item 404(a)
Financial Impact
No financial impact — routine board appointment with no disclosed compensation or material agreement
Risk Factors
- No financial terms disclosed — compensation structure unknown
- Farrow's multiple board seats (Clover Biopharmaceuticals, Achieve Life Sciences) could create time constraints
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-039602 |
| Document: ef20083796_ex99-1.htm | 0001140361-26-039602 |
| Document: 0001140361-26-039602-index-headers.html | 0001140361-26-039602 |
| Document: 0001140361-26-039602-index.html | 0001140361-26-039602 |
| Document: 0001140361-26-039602.txt | 0001140361-26-039602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | DEF 14A | $1.00 | awaiting T+60 | — | $1.06 (−6.00%) |
Oct 14, 2026 12d ago | 8-K | $1.07 | awaiting T+60 | — | $1.06 (−0.93%) |
Sep 17, 2026 5w ago | 8-K | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Sep 17, 2026 5w ago | Press Release | $1.74 | awaiting T+60 | — | $1.06 (−39.08%) |
Aug 4, 2026 11w ago | 8-K | $1.14 | awaiting T+60 | — | $1.06 (+7.02%) |
Jul 24, 2026 13w ago | 8-K | $1.67 $1.00 | ▲ +40.12% | ▲ +43.41% | $1.06 (+36.53%) |
Jul 17, 2026 14w ago | 8-K | $3.60 $1.05 | ▼ −70.79% | ▼ −75.48% | $1.06 (−70.51%) |
Jun 10, 2026 19w ago | Press Release | $3.61 $1.64 | ▼ −54.57% | ▼ −61.15% | $1.06 (−70.64%) |
Jun 9, 2026 19w ago | 8-K | $3.46 $1.57 | ▲ +54.62% | ▲ +58.44% | $1.06 (+69.36%) |
Jun 1, 2026 21w ago | 8-K | $3.58 $1.74 | ▲ +51.40% | ▲ +52.63% | $1.06 (+70.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers